| Michael Widjaja, MD | |
|
299 Kings Daughters Dr, Frankfort, KY 40601-4186 | |
| (502) 875-5240 | |
| Not Available |
| Full Name | Michael Widjaja |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 299 Kings Daughters Dr, Frankfort, Kentucky |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184285249 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 56540 (Kentucky) | Primary |
| Entity Name | Hospital Medicine Services Of Ky, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215634373 PECOS PAC ID: 0244695104 Enrollment ID: O20230427001527 |
News Archive
Global warming is likely to increase the proportion of the population affected by kidney stones by expanding the higher-risk region known as the "kidney-stone belt" into neighboring states, researchers at UT Southwestern Medical Center and UT Dallas have found.
There is little evidence to support the use of atypical antipsychotic drugs for some treatments other than their officially approved purposes, even though many clinicians continue to commonly prescribe these drugs for so-called "off label" uses, according to a new report from the U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality.
A new study, conducted by the researchers from the University of Liverpool, published in JAMA Ophthalmology identifies the specific characteristics of Ebola retinal lesions, which provide further clues as to how the virus travels to the retina and causes damage.
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Widjaja, MD 2151 Meeting St Apt 12209, Lexington, KY 40509-4662 Ph: (347) 749-8428 | Michael Widjaja, MD 299 Kings Daughters Dr, Frankfort, KY 40601-4186 Ph: (502) 875-5240 |
News Archive
Global warming is likely to increase the proportion of the population affected by kidney stones by expanding the higher-risk region known as the "kidney-stone belt" into neighboring states, researchers at UT Southwestern Medical Center and UT Dallas have found.
There is little evidence to support the use of atypical antipsychotic drugs for some treatments other than their officially approved purposes, even though many clinicians continue to commonly prescribe these drugs for so-called "off label" uses, according to a new report from the U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality.
A new study, conducted by the researchers from the University of Liverpool, published in JAMA Ophthalmology identifies the specific characteristics of Ebola retinal lesions, which provide further clues as to how the virus travels to the retina and causes damage.
Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.
› Verified 3 days ago
Laurie Haas, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 299 Kings Daughters Dr, Frankfort, KY 40601 Phone: 502-875-5240 | |
Dr. Roger W Strunk, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 593 East Main Street, Frankfort, KY 40601 Phone: 502-223-0308 Fax: 502-227-5764 | |
Paran Saranga, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 859b East Main Street, Frankfort, KY 40601 Phone: 502-223-2011 | |
Dr. Stephen J Neustat, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 108 Diagnostic Dr, Frankfort, KY 40601 Phone: 502-227-5171 Fax: 502-227-0131 | |
Abdolkarim Tahanasab, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 6 Physicians Park, Frankfort, KY 40601 Phone: 502-875-1559 | |
Yuri Boyechko, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 299 Kings Daughters Dr, Frankfort, KY 40601 Phone: 000-000-0000 |